首页> 美国卫生研究院文献>Oncotarget >Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
【2h】

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

机译:microRNA相关基因多态性在局部晚期直肠癌患者对新辅助放化疗的病理完全反应中的预测作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In rectal cancer, a pathologic complete response (pCR) to pre-operative treatment is a favourable prognostic marker, but is reported in a minority of the patients. We aimed at identifying microRNA-related host genetic polymorphisms predictive of pCR.A panel of 114 microRNA-related tagging polymorphisms was selected and analyzed on 265 locally advanced rectal cancer patients treated with neoadjuvant chemo-radiotherapy. Patients were stratified in two subgroups according to the radiotherapy dose (50.4Gy for 202 patients, 55.0Gy for 78 patients). Interactions among genetic and clinical-pathological variants were investigated by recursive partitioning analysis.Only polymorphisms with a consistent significant effect in the two subgroups of patients were selected as predictive markers of pCR. The results were validated by bootstrap analysis. SMAD3-rs744910, SMAD3-rs745103, and TRBP-rs6088619 were associated to an increased chance of pCR (p=0.0153, p=0.0471, p=0.0125). DROSHA-rs10719 and SMAD3-rs17228212 had an opposite detrimental effect on pathological tumour response (p=0.0274, p=0.0049). Recursive partitioning analysis highlighted that a longer interval time between the end of radiotherapy and surgery increases the chance of pCR in patients with a specific combination of SMAD3-rs744910 and TRBP-rs6088619 genotypes.This study demonstrated that microRNA-related host genetic polymorphisms can predict pCR to neo-adjuvant chemo-radiotherapy, and could be used to personalize the interval time between the end of radiotherapy and surgery.
机译:在直肠癌中,对术前治疗的病理完全缓解(pCR)是一种有利的预后指标,但在少数患者中已有报道。我们旨在鉴定可预测pCR的与microRNA相关的宿主遗传多态性。选择了114个与microRNA相关的标记多态性的面板,并对265例接受新辅助化学放疗的局部晚期直肠癌患者进行了分析。根据放疗剂量将患者分为两个亚组(202例患者为50.4Gy,78例患者为55.0Gy)。通过递归分配分析研究了遗传变异和临床病理变异之间的相互作用,仅选择在两个亚组患者中具有一致显着效果的多态性作为pCR的预测标志物。通过引导分析验证了结果。 SMAD3-rs744910,SMAD3-rs745103和TRBP-rs6088619与pCR机会增加相关(p = 0.0153,p = 0.0471,p = 0.0125)。 DROSHA-rs10719和SMAD3-rs17228212对病理性肿瘤反应具有相反的有害作用(p = 0.0274,p = 0.0049)。递归分区分析显示,SMAD3-rs744910和TRBP-rs6088619基因型特定组合的患者放疗和手术结束之间的间隔时间更长,增加了pCR的机会。这项研究表明,与microRNA相关的宿主遗传多态性可以预测pCR新辅助化疗放疗,可用于个性化放疗结束与手术之间的间隔时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号